Isotretinoine in the treatment of rosacea
- Authors: SAMTSOV AV1, GORBUNOV YG1
-
Affiliations:
- ФГВОУ ВПО «Военно-медицинская академия им. С.М. Кирова» МО РФ
- Issue: Vol 88, No 4 (2012)
- Pages: 102-104
- Section: Articles
- URL: https://ogarev-online.ru/0042-4609/article/view/117233
- DOI: https://doi.org/10.25208/vdv715
- ID: 117233
Cite item
Full Text
Abstract
Goal: Evaluation of isotretinoine acnecutane) in small doses (0,2 mg/kg/day) in the treatment of papulopustular stage of rosacea. Маterials and methods. 21 patients with papulopustular version of rosacea, not responding to traditional therapeutic methods have been examined. Patients were receiving small doses of isotretinoine acnecutane) (0,2 mg/kg/day). The efficiency of the performed therapy was evaluated with the dermatologic index of life quality. Results. The research has demonstrated the high efficiency of isotretinoine acnecutane) in the treatment of papulopustular stage of rosacea. The use of small doses of the substance allowed to minimize side effects, which can take place at the background of isotretinoine (acnecutane), providing the high safety of it’s application.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
A V SAMTSOV
ФГВОУ ВПО «Военно-медицинская академия им. С.М. Кирова» МО РФ
Email: avsamzsov@mail.ru
д.м.н., профессор, заведующий кафедрой кожных и венерических болезней Санкт-Петербург
Y G GORBUNOV
ФГВОУ ВПО «Военно-медицинская академия им. С.М. Кирова» МО РФдоцент кафедры кожных и венерических болезней Санкт-Петербург
References
- Bamford J. Rosacea: current thouthts on origin. Semin Cutan Med Surg 2001; 20: 199—206.
- Zuber T. Rosacea. Prim Care 2000; 27: 309—318.
- Park Н., James Q. Del Rosso. Use of Oral Isotretinoin in the Management of Rosacea J Clin Aesthetic Derm 2011; 9: 54—61.
- Sobottka A., Lehmann P. Rosacea 2009: new advances in pathophysiology, clinical staging and therapeutic strategies, Hautarzt 2009: 60: 999—1009.
- Elewsky B., Draelos Z., Dreno B. Rosacea — global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. JEADV 2011; 25: 188—200.
- Crawford G., Pelle M., James W. J Am Acad Dermatol 2004; 46: 327—341.
- Schmidt J., Gebhart W., Raff M., Spona J. 13-cis-Retinoic acid inrosacea. Clinical and laboratory findings. Acta Derm Venereol 1984; 64: 15—21.
- Plewig G., Nikolowski J., Wolff H. Action of isotretinoin in acne rosacea and gram-negative folliculitis. J Am Acad Dermatol 1982; 6: 766—785.
- Hoting E., Paul E., Plewig G.Treatment of rosacea with isotretinoin. Int J Dermatol 1986; 25: 660—663.
- Marsden J., Shuster S., Neugebauer M. Response of rosacea to isotretinoin. Clin Exp Dermatol 1984; 9: 484—488.
- Gajardo J. Severe rosacea treated with oral isotretinoin. Rev Med Chil 1994; 122: 177—179.
- Gollnick H., Blume-Peytavi U., Szabo E, et al. Systemic isotretinoin in thetreatment of rosa-cea—doxycycline and placebo-controlled, randomized clinical study. J Dtsch Dermatol Ges. 2010; 8: 505—515.
- Hofer T. Continuous “microdose” isotretinoin in adult recalcitrantrosacea. Clin Exp Dermatol 2004; 29: 204—205.
- Thielitz A., Gollnick H. Rosacea. Systemic therapy with retinoids. Hautarzt 2011; 62: 820—827.
- Nikolowski J., Plewig G., Hofmann C. In-vivo-Test zum Nachweis derantiinflammatorischen Wirkung der13-cis-Retinsaure. Dermatol Monatsschr. 1982; 168: 173—181.
- Dispenza M., Wolpert E., Gilliland L. et al. Systemic Isotretinoin Therapy Normalizes Exaggerated TLR-2-Mediated Innate Immune Responses in Acne Patients. J Invest Dermatol. 2012 Apr 19.doi: 10.1038/jid.2012.111.
- Irvine C., Kumar P., Marks R.Isotretinoin in the treatment of rosacea and rhinophyma. In: Marks R., Plewig G, eds. Acne and Related Disorders: Proceedings of an International Symposium. London: Martin Dunitz; 1988: 301—305.
- Van Zuuren E., Gupta A., Gover M. et al. Systematic review of rosacea treatment J Am Acad Dermatol 2007; 56: 107—115.
Supplementary files
